Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice

BACKGROUND: Immune checkpoint inhibitors (ICIs) are used widely for treating metastatic urothelial carcinoma (mUC). In practical settings, evidence is lacking on the efficacy of ICIs in some difficult-to-treat patients, such as those with end-stage renal disease (ESRD). Herein, we evaluate the safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Ming-Chun, Su, Po-Jung, Huang, Chun-Chieh, Luo, Hao-Lun, Chiu, Tai-Jan, Li, Shau-Hsuan, Wu, Chia-Che, Liu, Ting-Ting, Cheng, Yuan-Tso, Kang, Chih-Hsiung, Su, Yu-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729012/
https://www.ncbi.nlm.nih.gov/pubmed/33330066
http://dx.doi.org/10.3389/fonc.2020.584834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729012/
https://www.ncbi.nlm.nih.gov/pubmed/33330066
http://dx.doi.org/10.3389/fonc.2020.584834

Ejemplares similares